The histone deacetylase 4/SP1/microrna‐200a regulatory network contributes to aberrant histone acetylation in hepatocellular carcinoma

As an important epigenetic mechanism, histone acetylation modulates the transcription of many genes and plays important roles in hepatocellular carcinoma (HCC). Aberrations in histone acetylation have been observed in HCC, but the factors that contribute to the aberrations have not been fully elucidated. MicroRNAs (miRNAs), which are noncoding RNAs that regulate gene expression, are involved in important epigenetic mechanisms. In this study, we determined that miR‐200a and the level of histone H3 acetylation at its promoter were reduced in human HCC tissues in comparison with adjacent noncancerous hepatic tissues. Furthermore, our results suggested that the histone deacetylase 4 (HDAC4) inhibited the expression of miR‐200a and its promoter activity and reduced the histone H3 acetylation level at the mir‐200a promoter through a Sp1‐dependent pathway. Interestingly, we observed that the miR‐200a directly targeted the 3′‐untranslated region of the HDAC4 messenger RNA and repressed expression of HDAC4. Therefore, miR‐200a ultimately induced its own transcription and increased the histone H3 acetylation level at its own promoter. Through targeting HDAC4, miR‐200a also induced the up‐regulation of total acetyl‐histone H3 levels and increased the histone H3 acetylation level at the p21WAF/Cip1 promoter. Finally, we determined that miR‐200a inhibited the proliferation and migration of HCC cells in vivo and in vitro. Conclusion: Our findings suggest that the HDAC4/Sp1/miR‐200a regulatory network induces the down‐regulation of miR‐200a and the up‐regulation of HDAC4 in HCC. As a result, down‐regulation of miR‐200a enhances the proliferation and migration of HCC cells and induces aberrant histone acetylation in HCC. These findings highlight a potential therapeutic approach in targeting the HDAC4/Sp1/miR‐200a regulatory network for the treatment of HCC. (HEPATOLOGY 2011

[1]  Shuhan Sun,et al.  Up‐regulated microRNA‐143 transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis by repressing fibronectin expression , 2009, Hepatology.

[2]  Lewis R. Roberts,et al.  Hepatocellular carcinoma: a global view , 2010, Nature Reviews Gastroenterology &Hepatology.

[3]  司履生 Cancer epigenetics , 2006 .

[4]  Lin He,et al.  MicroRNAs: small RNAs with a big role in gene regulation , 2004, Nature Reviews Genetics.

[5]  A. Roccaro,et al.  microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia. , 2010, Blood.

[6]  Andrew J. Wilson,et al.  HDAC4 promotes growth of colon cancer cells via repression of p21. , 2008, Molecular biology of the cell.

[7]  G. Goodall,et al.  The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice. , 2011, The Journal of clinical investigation.

[8]  V. Castronovo,et al.  HDAC4 represses p21WAF1/Cip1 expression in human cancer cells through a Sp1-dependent, p53-independent mechanism , 2009, Oncogene.

[9]  V. Richon,et al.  Aminosuberoyl hydroxamic acids (ASHAs): a potent new class of HDAC inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[10]  H. Fang,et al.  The structure and function of histone deacetylases: the target for anti-cancer therapy. , 2008, Current medicinal chemistry.

[11]  D. Bartel MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[12]  Asad U. Khan,et al.  Role of histone acetylation in cell physiology and diseases: An update. , 2010, Clinica chimica acta; international journal of clinical chemistry.

[13]  Shuhan Sun,et al.  miR‐17‐5p Promotes migration of human hepatocellular carcinoma cells through the p38 mitogen‐activated protein kinase‐heat shock protein 27 pathway , 2010, Hepatology.

[14]  C. Croce,et al.  MicroRNA involvement in hepatocellular carcinoma , 2008, Journal of cellular and molecular medicine.

[15]  P. Laird Cancer epigenetics. , 2005, Human molecular genetics.

[16]  S. Sharma,et al.  Deficient histone acetylation and excessive deacetylase activity as epigenomic marks of prostate cancer cells. , 2009, International journal of oncology.

[17]  F. Huang,et al.  Effect of trichostatin a on viability and microRNA expression in human pancreatic cancer cell line BxPC-3. , 2008, Experimental oncology.

[18]  Tae Jin Lee,et al.  p53 regulates epithelial–mesenchymal transition through microRNAs targeting ZEB1 and ZEB2 , 2011, The Journal of experimental medicine.

[19]  E. Olson,et al.  The many roles of histone deacetylases in development and physiology: implications for disease and therapy , 2009, Nature Reviews Genetics.

[20]  C. Benz,et al.  Rapid alteration of microRNA levels by histone deacetylase inhibition. , 2006, Cancer research.

[21]  P. Atadja HDAC inhibitors and cancer therapy. , 2011, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[22]  M. Grunstein,et al.  Functions of site-specific histone acetylation and deacetylation. , 2007, Annual review of biochemistry.

[23]  H. El‐Serag,et al.  Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. , 2007, Gastroenterology.

[24]  F. Dequiedt,et al.  Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. , 2002, Molecular cell.

[25]  Qun Zhou,et al.  miR-200a Regulates SIRT1 Expression and Epithelial to Mesenchymal Transition (EMT)-like Transformation in Mammary Epithelial Cells* , 2011, The Journal of Biological Chemistry.

[26]  K. Gunsalus,et al.  Combinatorial microRNA target predictions , 2005, Nature Genetics.

[27]  J. Llovet,et al.  Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. , 2010, Seminars in liver disease.

[28]  Yue Wang,et al.  Down‐regulated microRNA‐152 induces aberrant DNA methylation in hepatitis B virus–related hepatocellular carcinoma by targeting DNA methyltransferase 1 , 2010, Hepatology.

[29]  T. Okanoue,et al.  Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues , 2006, Oncogene.

[30]  G. Goodall,et al.  The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 , 2008, Nature Cell Biology.

[31]  R. Büttner,et al.  Global histone acetylation levels: Prognostic relevance in patients with renal cell carcinoma , 2010, Cancer science.

[32]  M. F. Shannon,et al.  A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. , 2008, Cancer research.

[33]  A. van Oudenaarden,et al.  MicroRNA-mediated feedback and feedforward loops are recurrent network motifs in mammals. , 2007, Molecular cell.

[34]  O. Witt,et al.  HDAC family: What are the cancer relevant targets? , 2009, Cancer letters.

[35]  T. Hibi,et al.  Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells , 2009, Oncogene.

[36]  Xuegong Zhang,et al.  An overview of hepatocellular carcinoma study by omics-based methods. , 2009, Acta biochimica et biophysica Sinica.

[37]  R. Place,et al.  miR-449a targets HDAC-1 and induces growth arrest in prostate cancer , 2009, Oncogene.

[38]  C. Morrison,et al.  MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B , 2007, Proceedings of the National Academy of Sciences.

[39]  Jian-Fu Chen,et al.  The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation , 2006, Nature Genetics.

[40]  T. Liang,et al.  Overexpression of myocyte enhancer factor 2 and histone hyperacetylation in hepatocellular carcinoma , 2007, Journal of Cancer Research and Clinical Oncology.

[41]  C. Zhang,et al.  Transcriptional silencing of the TMS1/ASC tumour suppressor gene by an epigenetic mechanism in hepatocellular carcinoma cells , 2007, The Journal of pathology.

[42]  Hao Jiang,et al.  HDAC4 inhibits the transcriptional activation of mda-7/IL-24 induced by Sp1 , 2010, Cellular and Molecular Immunology.